Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

73.80 -0.05 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,135,216
Open 73.28
Bid (Size) 73.02 (100)
Ask (Size) 80.00 (200)
Prev. Close 73.85
Today's Range 71.99 - 74.11
52wk Range 43.17 - 87.50
Shares Outstanding 81,474,366
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool

Performance

YTD
-3.8%
-3.8%
1 Month
+13.3%
+13.3%
3 Month
+11.2%
+11.2%
6 Month
-6.8%
-6.8%
1 Year
+51.1%
+51.1%

More News

Read More
News headline image
PTC Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT) Delivers Q1 Earnings Beat and Raises 2026 Guidance ↗
Via Chartmill
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
Via Chartmill
News headline image
PTCT Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
Via Chartmill
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
Via Chartmill
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 73.80
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 06/01/26 04:00 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 6.01B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article